Successful performance and execution of rapid diagnostics in a clinical laboratory hinges heavily on careful validation, accurate and timely communication of results, and real-time quality monitoring. Laboratories must develop strategies to integrate diagnostics with stewardship and evidence-based clinical practice guidelines. We present a collaborative SUCCESS model for execution and monitoring of rapid sepsis diagnostics to facilitate timely treatment. Six months after execution of the Verigene Gram-Positive Blood Culture (BC-GP) and the AdvanDx PNA-FISH assays, data were collected on 579 and 28 episodes of bacteremia and fungemia, respectively. Clinical testing was executed using a SUCCESS model comprising the following components: stewardship, utilization of resources, core strategies, concierge services, education, support, and surveillance. Stewardship needs were identified by evaluating the specialty services benefiting from new testing. Utilization of resources was optimized by reviewing current treatment strategies and antibiogram and formulary options. Core strategies consisted of input from infectious disease leadership, pharmacy, and laboratory staff. Concierge services included automated Micro-eUpdate and physician-friendly actionable reports. Education modules were user-specific, and support was provided through a dedicated 24/7 microbiology hotline. Surveillance was performed by daily audit by the director. Using the SUCCESS model, the turnaround time for the detailed report with actionable guidelines to the physician was ~3 hours from the time of culture positivity. The overall correlation between rapid methods and culture was 94% (546/579). Discrepant results were predominantly contaminants such as a coagulase-negative staphylococci or viridans streptococci in mixed cultures. SUCCESS is a cost-effective and easily adaptable model for clinical laboratories with limited stewardship resources.
B
acteremia is a major cause of severe sepsis and septic shock, accounting for 30% to 40% of cases, with an estimate of about 250,000 cases occurring annually in the United States (1) . A signifi cant proportion of causative organisms are gram-positive bacteria, most commonly Staphylococcus species (2) . Multiple studies have established that timely administration of appropriate antibiotics signifi cantly reduces the mortality of severe sepsis and septic shock. Use of inappropriate empiric antibiotics is a common factor associated with mortality rates as high as 75% (3, 4) . Delays in initiating antimicrobial treatment are correlated with a progressive increase in mortality (5) . Th e choice of initial antibiotics for treatment of bacteremia must currently be determined empirically. A reduction in time to an accurate identifi cation and susceptibility results may lead to improved patient outcomes, although literature on the magnitude of such an eff ect is mixed (6, 7) .
Current standard blood culture procedures consist of inoculating a blood culture bottle and placing it on an automated continuous monitoring and alert platform (8) . Upon positivity, the contents are Gram stained, plated on appropriate media, and allowed to grow for 18 to 42 hours or longer, with subsequent subcultures and susceptibility testing as appropriate. Th e temporal delay between collection of a blood sample from a patient and availability of traditional identifi cation and susceptibility results has obvious implications regarding patient care.
Newer technologies such as nucleic acid amplifi cation tests, fl uorescence in situ hybridization (FISH), and matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry (MALDI-TOF MS) provide rapid identifi cation of pathogens and codetection of key resistance markers directly from positive blood cultures. Th e Verigene Gram-Positive (BC-GP) and Gram-Negative (BC-GN) blood culture assays are approved by the Food and Drug Administration (FDA) to detect common gram-positive and gram-negative organisms, respectively, and associated resistance markers within 3 hours from positive blood cultures (9) . Th e Verigene assays are nonamplifi ed tests that rely on nucleic acid extraction from positive blood cultures followed by microarray-based detection using capture and detection probes. BC-GP is specifi c for 12 gram-positive bacterial identifi cation targets and 3 associated resistance markers (mec A , van A , and van B ), while BC-GN is specifi c for 8 gram-negative bacterial identifi cation targets and 6 resistance markers (bla CTX-M , bla KPC , bla NDM , bla VIM , bla IMP , and bla OXA ). Th e turnaround time from positive blood culture to results can be markedly reduced compared with traditional methods, potentially providing
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Mhair Dekmezian, MD, Stacy G. Beal, MD, Mary Jane Damashek, MT (ASCP) SM, Raul Benavides, MD, and Neelam Dhiman, PhD clinically useful data hours or days before traditional methods. Peptide nucleic acid (PNA) FISH is also an FDA-approved technology that uses a PNA probe that hybridizes to the target rRNA when present in the sample and allows visualization of bacteria (such as Staphylococcus aureus/coagulase-negative staphylococci, Enterococcus faecalis/other enterococci, Escherichia coli, Klebsiella and Pseudomonas spp.) and yeasts (Candida spp.) in positive blood cultures within 1.5 hours of positivity (10) . Rapid identifi cation and resistance reporting may allow de-escalation of empiric coverage to appropriate targeted therapy and reduction in length of hospital stay.
In this prospective study, we evaluated the laboratory performance of two rapid molecular tests, Verigene BC-GP and Yeast Traffi c Light PNA FISH, on a cohort of inpatients from Baylor University Medical Center at Dallas and regional hospitals in Dallas, Texas. In addition, we developed a logical execution protocol to ensure clinical "SUCCESS" of the laboratory testing.
MATERIALS AND METHODS
Laboratory performance and execution of rapid diagnostics was based on seven key components of the SUCCESS model ( Figure 1 ). Standardized treatment guidelines were developed by a collaborative team of infectious disease specialists, pharmacists, and laboratory directors. To support an antimicrobial stewardship program team with limited fi nancial and personnel resources, a strategy to bypass pharmacy intervention and include treatment recommendations on the report was chosen for timely and eff ective communication of the results to the users. Stewardship recommendations and algorithms for possible test result scenarios were formulated after the review of institutional treatment strategies, practices and interventions based on conventional microbiology testing results, and antibiogram and formulary options. In addition, comments were developed to address possible limitations of the assay to avoid adverse patient outcomes. Extensive materials were developed for training and education. Electronic tools were developed for daily updates, surveillance, and audit of results.
For monitoring the performance of the executed tests in routine three-shift microbiology laboratories, results were audited for a period of 6 months after the go-live date. A total of 15,793 blood cultures were performed during this period. Blood cultures with positive alerts from the BacT/ALERT system (bioMérieux, Inc., Durham, NC) containing gram-positive cocci (n = 579) and/or yeast (n = 28) were tested according 
Surveillance
•Develop electronic reports to abstract rapid test data and culture data for prospective daily audit of results •Develop templates to monitor key parameters such as culture correlation, error rate, repeat rate and turn around time •Design outcome study to measure the impact of rapid testing and stewardship •Identify "non-adopters" and re-educate to manufacturer procedures using the FDA-approved BC-GP (Nanosphere, Northbrook, IL) and Yeast PNA FISH assay (AdvanDX, Woburn, MA), respectively. Any results indicating no organisms detected or an internal control failure were refl exively repeated. Concurrent with the BC-GP and PNA-FISH testing, traditional laboratory procedures were also used to identify causative organisms, including plating on appropriate media and the routine biochemical and antibiotic susceptibility tests.
Results from rapid testing were compared with biochemical testing for concordance in identifi cation and antibiotic susceptibility. Turnaround time analysis was measured from the time of Gram stain following culture bottle positivity to the availability of rapid assay results.
RESULTS
Th e execution model was direct communication of a detailed report with actionable guidelines to the physicians within 3 hours from the time of culture positivity using the laboratory and hospital information systems in addition to critical calls. Tables 1 and 2 outline the comments that were incorporated in the Verigene and PNA-FISH reports, respectively. Briefl y, the initial Gram stain was reported with a critical call as routine. Th e report was updated with the Verigene or PNA-FISH results and the applicable stewardship comment within 1.5 hours for yeasts and 3 hours for bacteria. A second critical call was initiated at this time to communicate the result update to the physicians. Subsequently, the identifi cation by conventional methods from culture and susceptibility results was communicated when available. Careful consideration was given to communicate the limitations of the assay with appropriate canned comments. For example, in an event of codetection of S. aureus, S. epidermidis, and mec A targets, a comment was added to specify that methicillin resistance was detected but could not be assigned to either S. aureus or S. epidermidis, and the recommendation was made to refer to the fi nal pathogen identifi cation and sensitivities to prevent premature change in management. Similarly, a comment was added to address the cross-reactivity of S. pneumoniae with other members of the S. mitis group. All not-detect calls also went out with a recommendation to refer to fi nal identifi cation and sensitivities to prevent misinterpreting a not-detect call as negative for targets that were not present on the BC-GP panel (Table 1) .
For periodic cumulative updates to the physicians, an automated personalized Micro eUpdate service was provided. Th is service sent a summary of updated microbiology results by physician/physician group every 6 hours via a secure email. Th is provided easy access to results when the electronic medical record might not be easily accessible. A cumulative electronic report on Verigene and PNA-FISH results from the prior 24 hours was also sent to the pharmacist every morning. Th is allowed the pharmacist to monitor compliance with treatment recommendations and identify and target "nonadopters" for additional education. Using this approach, we were able to target 64% uptake at execution and ∼80% uptake after 3 months of execution after additional education (data not shown). Performance of the tests was evaluated by daily audit and correlation with the conventional results. During the 6-month period, 579 blood cultures were assayed, of which 525 were monomicrobial and 54 were polymicrobial in culture. Th e correlation between the results by conventional methods and the Verigene BC-GP assay were 97% (508/525) for monomicrobial (Table 3 ) and 70% (38/54) for polymicrobial cultures (Table 4) , with an overall correlation rate of 94% (546/579). Th e average turnaround time from Gram stain to Verigene reporting was 3.1 ± 1.1 hours.
Th ere were seven errors with major clinical impact in the monomicrobial cultures, which included miscalling S. aureus as coagulase-negative staphylococci (n = 3), failure to identify the mec A marker in an S. aureus isolate (n = 1), and miscalling S. agalactiae as coagulase-negative staphylococci (n = 3). Th e highest proportion (47.06%) of errors was due to the inability to detect viridans streptococci (n = 5) or S. pyogenes (n = 3) (Table 3) . For polymicrobial cultures, the majority of the misses were coagulase-negative staphylococci and/or viridans streptococci with or without a non-BC-GP target. Th ere was one mixed culture with Streptococcus spp. and methicillin-resistant Staphylococcus aureus, where Verigene missed S. aureus and the associated mec A target. Another mixed culture miscalled the van A marker in a mix of E. faecalis and a non-BC-GP target, Enterobacter cloacae (Table 4) .
In 41 instances the BC-GP molecular assay failed to identify any organisms, including the non-BC-GP targets such as Abiotrophia spp., Bacillus spp., Aerococcus spp., Actinomyces spp., Acinetobacter spp., anaerobic gram-positive cocci, Corynebacterium spp., Clostridium perfringens, Escherichia coli, Enterococcus casselifl avus, E. gallinarum, and Micrococcus spp. Th e most common organism associated with the not-detected call was Micrococcus spp. (n = 25).
PNA FISH analysis of 28 blood cultures containing yeast on Gram stain yielded identification of C. albicans/parapsilosis (n = 21), C. glabrata/krusei (n = 4), and C. tropicalis (n = 1). Two specimens were not-detect call by PNA-FISH and were identifi ed as Cryptococcus neoformans after routine laboratory culture and identifi cation methods. PNA-FISH gave accurate results for the two specimens mixed with bacterial targets. Th e average turnaround time from Gram stain to PNA-FISH reporting was ∼1.5 hours.
DISCUSSION
Th e validation of newer techniques is a vital component in the endless process of laboratory improvement. Th ere is substantial data in the literature to support the superior laboratory performance and better turnaround time of new diagnostics such as Verigene and PNA-FISH compared to conventional methods for sepsis (11) (12) (13) (14) (15) . However, limited guidance is available for integration of such techniques into the laboratory workfl ow, and the subsequent introduction to the clinical setting reveals a separate set of challenges. In this study, we sought to evaluate both the validity of the laboratory portion of the molecular assay in a true clinical setting along with the execution and uptake of the results by the end users.
Th e laboratory performance for BC-GP in our study was comparable to that of published reports. Th e overall concordance between the Verigene BC-GP assay and the expected results (i.e., correct identifi cation of targeted organisms and susceptibility) using conventional testing was 94%. Many of the discrepancies were related to organisms of little relative clinical signifi cance, such as S. epidermidis or another coagulase-negative staphylococcus in a single blood culture set, or where there was another accurately reported pathogenically dominant organism in a mixed culture (such as pneumococcus alongside coagulasenegative staphylococcus). Other discrepancies included clinically relevant gram-positive rods, which were not the targets of the molecular assay. One notable discrepancy in our study was a 50% (3 of 6 cultures) failure rate of the BC-GP assay to detect Group A streptococcus. Th is was realized as a limitation of the assay. Group A streptococcus harbors cell-wall-located DNase, which serves as an important virulence factor in pathogenesis (16) . Th e DNases are also known to degrade the internal processing control that comprises a nontarget organism, Bacillus subtilis, which invalidated the result. Despite signifi cant literature on analytical and laboratory validation of rapid diagnostics, there are a handful of reports in the literature that have looked at the clinical and economic outcomes for patients after successful execution. Sango et al (17) evaluated the impact of Enterococcus identifi cation and resistance detection using Verigene BC-GP. Th e intervention by an infectious disease and/or critical care pharmacist on 74 patients with enterococcal bacteremia led to a signifi cant decrease in the mean time to appropriate antimicrobial therapy in the postintervention group (23.4 h; P = 0.005) compared with the preintervention group. Alby et al (18) developed a treatment algorithm for streptococci and enterococci identifi ed with the Verigene BC-GP assay in collaboration with their institutional antimicrobial stewardship program. However, the execution plan and algorithm utilization still relied on eff ective manual communication of the BC-GP results directly to an on-call pharmacist, who in turn used the treatment algorithm as a guide when recommending therapy at the bedside. Bauer et al (19) also used direct phone contact with the infectious diseases pharmacist as an eff ective mode of communication with results of the rapid PCR for methicillin-resistant S. aureus/S. aureus bacteremia. Clinical and economic outcome evaluation on 156 patients showed that the mean time to switch from empiric vancomycin to cefazolin or nafcillin in patients with methicillin-susceptible S. aureus bacteremia was 1.7 days shorter (P = 0.002), the mean length of stay was 6.2 days shorter (P = 0.07), and the mean hospital costs were $21,387 less (P = 0.02) after PCR. However, none of these studies demonstrated an eff ective execution plan for an in-hospital or reference laboratory serving a hospital with limited staff available for routine stewardship. In addition, the additional cost incurred due to extended stewardship resources is not accounted for in the cost evaluation.
To our knowledge, this is a fi rst communication that describes the eff ective execution of rapid molecular diagnostics for sepsis without direct involvement of an infectious disease pharmacist or physician for routine stewardship recommendations. Using our SUCCESS approach, we have eliminated the additional cost and time related to a pharmacist's intervention. Using our model, the execution of the molecular testing procedures into the laboratory and clinical reporting workfl ow went smoothly, with technologist training, bench-aids, daily audits, and easy access to technical and scientifi c guidance all contributing to smooth integration of the new methods. In general, the ordering clinicians viewed the newly available type of data generated by the molecular assay as positive and useful in the patient management workfl ow, based on feedback provided to the microbiology hotline, as well as email and verbal communications. Th e high rate of correlation between rapid methods and culture validates the usefulness of the BC-GP molecular assay in a clinical laboratory workfl ow for providing proper and rapid patient management. Th e impact on clinical outcomes from this study is addressed in a separate communication (20) . Briefl y, we demonstrated a signifi cant decrease (P < 0.05) in time from collection to the fi rst dose of appropriate antibiotics for patients with methicillin-sensitive Staphylococcus aureus and vancomycin-resistant enterococci. Additionally, the percent of patients on empiric therapy who were placed on appropriate antibiotics after the Gram stain result was available increased from 64% pre-BC-GP to 80% post-BC-GP (20) .
As with any other technology, there are several limitations of the BC-GP assay. First, it can only report from a small set of organisms, and some of those are called only to genus level. While the majority of bacteremia cases are due to specifi cally targeted organisms, the clinical reality is that there may be a nontrivial amount of bacteremia due to other nonpredominating organisms. Second, the resistance markers cannot be assigned to a particular marker in a mixed culture. Th is is particularly an issue when S. aureus, S. epidermidis, and mec A are concurrently detected. A resolution by conventional testing is required for such cases. Lastly, the assay cannot diff erentiate between S. pneumoniae and the S. mitis/oralis group. False-positive S. pneumoniae does not limit the utility of the assay, as treatment algorithms can be developed around this limitation by eff ective communication of the results and assay limitations (18) .
